RxDoctor Payments Data

Dana Winn, MD

Family Medicine · Clemmons, NCNPI 1508024290

Payments from drug & device makers

$365in general payments, 2019–2025

Across 20 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$149
  • Novo Nordisk$104
  • Dexcom, Inc.$27
  • Irhythm Technologies, Inc.$26
  • Dynavax Technologies Corporation$17
  • AbbVie$15
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$35497%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$365 in reported general payments places this provider in the 50th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,864
Medicare patients
70
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide116$127,690
EliquisApixaban43$42,921
OzempicSemaglutide25$36,931
JardianceEmpagliflozin28$28,873
RybelsusSemaglutide11$27,870
WegovySemaglutide17$25,313
JanuviaSitagliptin Phosphate28$23,729
Repatha SureclickEvolocumab23$19,762
FarxigaDapagliflozin Propanediol12$17,746
LinzessLinaclotide23$16,505
XareltoRivaroxaban12$14,041
MyrbetriqMirabegron13$7,669
GraliseGabapentin11$6,605
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$4,478
Incruse ElliptaUmeclidinium Bromide11$4,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$149$127,690116 claims
Novo NordiskOzempic, Rybelsus, Wegovy$104$90,11453 claims
Boehringer IngelheimJardiance$15$28,87328 claims
AbbVieLinzess, Synthroid$15$18,25540 claims
AstraZenecaFarxiga$12$17,74612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Clemmons

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →